If you’ve been considering aesthetic medicine, 2026 may be the best entry window in years — a documented provider shortage, a wave of new patients, and a training path that’s more accessible than most providers realize. Here’s the realistic roadmap.
Patients are arriving at aesthetic and weight management practices asking about NAD+. Here’s the clinical case for IV delivery, what the evidence actually shows, and how to build it into a practice already serving this patient.
63% of patients on GLP-1 medications are new to aesthetics — and they’re arriving with a distinct presentation that requires a different clinical and business approach. Here’s what GLP-1 aesthetic patients actually need from their provider, and how to build a practice model that serves them well.
April 2026 brought a wave of regulatory and clinical developments that GLP-1 providers need to act on before summer. From a landmark FDA compounding proposal to the Medicare GLP-1 Bridge program’s July 1 launch, here is what changed and what it means for your practice.
March 2026 delivered some of the most consequential GLP-1 news of the year — from a sweeping FDA enforcement action against telehealth compounders to the approval of Foundayo, the first oral GLP-1 with no food or water restrictions. Here’s what every provider needs to know this month.
Two oral GLP-1 medications for obesity are now FDA-approved — Eli Lilly’s Foundayo (orforglipron) and Novo Nordisk’s Wegovy pill (semaglutide 25 mg) — and they are meaningfully different. This clinical comparison breaks down the trial data, dosing requirements, and pricing so providers can have informed conversations with patients.
Insurance-based practice has become one of the leading structural drivers of physician burnout — but the solution is not a wellness seminar. For a growing number of physicians, cash-based aesthetic medicine is the deliberate exit strategy that removes the administrative burden and puts them back in control of their time and income.
Learn how long Mounjaro® stays in your system in this comprehensive guide.
Discover the key differences between Zepbound® and Wegovy® in our comparison. Understand their effectiveness and benefits for obesity and weight management.
MIC Injections (“Fat Burning”) and Their Role in Weight Management MIC is an acronym for the compounds: L-Methionine, Inositol and Choline. These are lipotropic agents